An observational study in Angiosarcoma, sponsored by Italian Sarcoma Group. Recruiting at 19 sites in Italy. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by Italian Sarcoma Group · Observational
This study will be a multi-institutional, prospective, observational study of patients with localized primary AS of any site within ISG and RTR centers. Patients will be treated according to clinical practice of the center and according to ISG clinical recommendations on localized AS.
The management of localized AS remains a clinical challenge and needs to be better defined and standardized, especially with regards to the role of radiation-therapy and systemic treatment. Several questions about the best treatment approach to some clinical presentations remain open and would need to be answered by clinical studies. Unfortunately, the rarity of this histology among sarcomas makes it challenging to carry out clinical studies in all such presentations. Moreover, prognostic factors are lacking and differences in epidemiological, pathological and clinical aspects between primary AS and secondary AS need to be better characterized.
These issues may be addressed with a prospective multi-institutional observational study, through the collection of clinical and pathological data of patients with localized AS.
Involving all reference centres for sarcoma in Italy, the Italian Sarcoma Group (ISG) will be the ideal network for this study, with the collaboration of the Italian Rare Cancer Network (RTR), a 7collaborative network among Italian centres focusing on improving the quality of care of patients with rare tumors.
99 studies on the registry are indexed under Hemangiosarcoma; 16 are open to participants now.
Browse Hemangiosarcoma studies →Italian Sarcoma Group is the lead sponsor of 31 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Exclusion Criteria: NA
* pathological diagnosis of AS; * any site of origin; * any age; * primary, localized, resectable disease.
Other: Observational
Observational
Demographic characteristics
Demographic data
Time frame: At the time of enrollment
General characteristics
Comorbidities
Time frame: At the time of enrollment
Cancer data
Previous cancer data
Time frame: At the time of enrollment
Origin of Tumor
Site of origin
Time frame: At the time of enrollment
Tumor characteristics
Multifocality
Time frame: At the time of enrollment
Tumor size
Size
Time frame: At the time of enrollment
Tumor aspects
Morphological aspects
Time frame: 10 years
Pathological characteristics
Proliferative index
Time frame: 10 years
Tumor phenotype
Tumor cell phenotype
Time frame: 10 years
Molecular characteristics
Molecular aspects
Time frame: 10 years
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Italian Sarcoma Group